EarningsQ1 2026 Earnings Report
MX:4528N Q1 2026 EPS Results
Actual EPS$5.98
Consensus EPS$4.04
Beat/MissBeat by +$1.94
One Year Ago EPS$4.38
MX:4528N Q1 2026 Revenue Results
Actual Revenue$13.51B
Expected Revenue$12.86B
Beat/MissBeat by +$650.39M
YoY Revenue Growth-8.92%
Earnings Announcement Details
QuarterQ1 2026
Date07/31/2026
TimeBefore Open
Conference CallFriday, July 31, 2026
MX:4528N Upcoming Earnings
ONO Pharmaceutical Co's next earnings date is estimated for October 29, 2026, based on past reporting schedules.
Q1 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q1 2026 Earnings Slide Deck
Q1 2026 Earnings Call Summary
Earnings Call Sentiment|Neutral
Mixed but balanced. The quarter delivered the company's highest-ever Q1 revenue (up 8.4% YoY) driven by strong FORXIGA performance and the addition of Deciphera (notably QINLOCK and ROMVIMZA). Strategic pipeline moves (povetacicept acquisition) and regulatory approvals/positive opinions support medium-term growth. However, near-term profitability was weakened by Deciphera operating losses, acquisition-related amortization and increased R&D/SG&A, while OPDIVO faces competitive pressure and slower recovery in lung cancer prescriptions. Management maintained full-year guidance, signaling confidence but with clear execution and timing risks.Company Guidance
Highest Q1 Revenue on Record
Revenue increased by JPY9.9 billion (8.4% YoY) to JPY127.5 billion, the highest Q1 sales in company history; sales revenue component rose JPY8.4 billion (10.6% YoY) to JPY87.8 billion and royalties/other increased JPY1.4 billion (3.7% YoY) to JPY39.8 billion.
Strong FORXIGA Performance
FORXIGA tablets grew JPY2.9 billion (13% YoY) to JPY25.1 billion, showing continued domestic strength across diabetes, chronic heart failure, and chronic kidney disease indications.
Deciphera Acquisition Driving Overseas Growth
Inclusion of Deciphera contributed JPY10.1 billion in sales in Q1. QINLOCK generated JPY8.9 billion in Q1 and is on track with the initial annual forecast of JPY34 billion; ROMVIMZA delivered JPY1.1 billion in Q1 with an expected annual run-rate around JPY5 billion as patient numbers grow.
Regulatory and Label Expansion Progress
Approvals and positive regulatory actions include OPDIVO + YERVOY approval for first-line hepatocellular carcinoma in Japan (June) and approvals in South Korea and Taiwan; subcutaneous OPDIVO approved in Europe; positive opinion from European Commission for ROMVIMZA (July); multiple pending filings progressing smoothly.
Pipeline Reinforcement via Strategic Licensing
Acquisition of development/commercial rights for povetacicept from Vertex (BAFF/APRIL dual antagonist) — Phase III for IgA nephropathy underway — positioned as potentially best-in-class mechanistically by inhibiting both BAFF and APRIL.
Domestic Rebound in Gastric Cancer New Prescriptions
OPDIVO new-prescription share in gastric cancer recovered from 57% to 65% in Q1 after competitive pressure; management target of 70% by year-end, supported by long-term follow-up and real-world data promotion.
Operational Discipline Outside Acquisition Effects
Excluding Deciphera, R&D expenses decreased YoY and SG&A (excluding FORXIGA co-promotion and Deciphera SG&A) remained at prior-year levels, indicating controlled spend on core operations.
Full-Year Guidance Unchanged
Company maintained its full-year earnings forecasts despite Q1 volatility and acquisition-related items, signaling confidence in hitting previously announced targets.
MX:4528N Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed